Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Use of colistin in adult patients: a cross-sectional study.

Giacobbe DR, Saffioti C, Losito AR, Rinaldi M, Aurilio C, Bolla C, Boni S, Borgia G, Carannante N, Cassola G, Ceccarelli G, Corcione S, Gasperina DD, De Rosa FG, Dentone C, Di Bella S, Di Lauria N, Feasi M, Fiore M, Fossati S, Franceschini E, Gori A, Granata G, Grignolo S, Grossi PA, Guadagnino G, Lagi F, Maraolo AE, Marinò V, Mazzitelli M, Mularoni A, Oliva A, Pace MC, Parisini A, Patti F, Petrosillo N, Pota V, Raffaelli F, Rossi M, Santoro A, Tascini C, Torti C, Trecarichi EM, Venditti M, Viale P, Signori A, Bassetti M, Del Bono V, Giannella M, Mikulska M, Tumbarello M, Viscoli C; SITA GIOVANI, (young investigators group of the Società Italiana Terapia Antinfettiva), the COLI-CROSS study group.

J Glob Antimicrob Resist. 2019 Jun 14. pii: S2213-7165(19)30153-5. doi: 10.1016/j.jgar.2019.06.009. [Epub ahead of print]

PMID:
31207379
2.

An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy.

Borgia G, Scotto R, Buonomo AR.

Expert Opin Investig Drugs. 2019 May;28(5):395-397. doi: 10.1080/13543784.2019.1602766. Epub 2019 Apr 10. No abstract available.

PMID:
30943797
3.

Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study.

Gentile I, Pinchera B, Viceconte G, Crispo M, Simeone D, Scotto R, Zappulo E, Maraolo AE, Paladino F, Tortora R, Di Costanzo GG, Buonomo A, Borgia G.

Infez Med. 2019 Mar 1;27(1):32-39.

4.

Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection.

Scotto R, Buonomo AR, Moriello NS, Maraolo AE, Zappulo E, Pinchera B, Gentile I, Borgia G.

Rev Recent Clin Trials. 2019 Mar 6. doi: 10.2174/1574887114666190306154650. [Epub ahead of print]

PMID:
30848211
5.

Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort).

Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T, Portunato F, De Pascalis S, Martini S, Macera M, Viceconte G, Tosone G, Buonomo AR, Borgia G, Coppola N.

Hepatol Int. 2019 Jan;13(1):66-74. doi: 10.1007/s12072-018-9914-6. Epub 2018 Dec 6.

PMID:
30523552
6.

The serum-ascites vitamin D gradient (SADG): A novel index in spontaneous bacterial peritonitis.

Buonomo AR, Arcopinto M, Scotto R, Zappulo E, Pinchera B, Sanguedolce S, Perruolo G, Formisano P, Cittadini A, Vespasiani Gentilucc U, Borgia G, Gentile I.

Clin Res Hepatol Gastroenterol. 2018 Oct 24. pii: S2210-7401(18)30214-6. doi: 10.1016/j.clinre.2018.10.001. [Epub ahead of print] No abstract available.

PMID:
30529022
7.

Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry.

Esposito S, De Simone G, Pan A, Brambilla P, Gattuso G, Mastroianni C, Kertusha B, Contini C, Massoli L, Francisci D, Priante G, Libanore M, Bicocchi R, Borgia G, Maraolo AE, Brugnaro P, Panese S, Calabresi A, Amendola G, Savalli F, Geraci C, Tedesco A, Fossati S, Carretta A, Santantonio T, Cenderello G, Crisalli MP, Schiaroli E, Rovere P, Masini G, Ferretto R, Cascio A, Colomba C, Gioè C, Tumbarello M, Losito AR, Foti G, Prestileo T, Buscemi C, Chiara I, Iacobello C, Sonia S, Starnini G, Ialungo A, Sapienza M; Italian Society of Infectious and Tropical Diseases.

J Chemother. 2019 Feb;31(1):9-14. doi: 10.1080/1120009X.2018.1536320. Epub 2018 Dec 3.

PMID:
30508410
8.

Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.

Buonomo AR, Saccà F, Zappulo E, De Zottis F, Lanzillo R, Gentile I, Carotenuto A, Borgia G, Russo CV.

Mult Scler Relat Disord. 2019 Jan;27:44-45. doi: 10.1016/j.msard.2018.09.031. Epub 2018 Oct 2.

PMID:
30316174
9.

Current evidence on the management of hepatitis B in pregnancy.

Maraolo AE, Gentile I, Buonomo AR, Pinchera B, Borgia G.

World J Hepatol. 2018 Sep 27;10(9):585-594. doi: 10.4254/wjh.v10.i9.585. Review.

10.

Prevalence of HSV1/2 Congenital Infection Assessed Through Genome Detection on Dried Blood Spot in Individuals with Autism Spectrum Disorders.

Zappulo E, Riccio MP, Binda S, Pellegrinelli L, Pregliasco F, Buonomo AR, Pinchera B, D'Urso G, Bravaccio C, Borgia G, Gentile I.

In Vivo. 2018 Sep-Oct;32(5):1255-1258. doi: 10.21873/invivo.11373.

11.

Current and emerging pharmacotherapy for the treatment of bacterial peritonitis.

Maraolo AE, Gentile I, Pinchera B, Nappa S, Borgia G.

Expert Opin Pharmacother. 2018 Aug;19(12):1317-1325. doi: 10.1080/14656566.2018.1505867. Epub 2018 Aug 2. Review.

PMID:
30071176
12.

Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study.

Gentile I, Fusco F, Buonomo AR, Scotto R, Zappulo E, Pinchera B, Persico F, Califano G, Borgia G, Longo N.

Sex Health. 2018 Nov;15(5):408-412. doi: 10.1071/SH17168.

PMID:
30045807
13.

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A; PITER Collaborating Group.

Liver Int. 2018 Dec;38(12):2190-2198. doi: 10.1111/liv.13901. Epub 2018 Aug 10.

14.

Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis.

Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I.

Expert Opin Drug Saf. 2018 Jul;17(7):709-717. doi: 10.1080/14740338.2018.1483330. Epub 2018 Jun 11. Review.

PMID:
29848085
15.

Response to: 'Letter to the Editor: "Management of multidrug-resistant Pseudomonas aeruginosa in the Intensive Care Unit: state of the art"'.

Maraolo AE, Cascella M, Corcione S, Cuomo A, Nappa S, Borgia G, De Rosa FG, Gentile I.

Expert Rev Anti Infect Ther. 2018 May;16(5):369-371. doi: 10.1080/14787210.2018.1473082. No abstract available.

PMID:
29723480
16.

NS5B polymerase inhibitors in phase II clinical trials for HCV infection.

Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR.

Expert Opin Investig Drugs. 2018 Mar;27(3):243-250. doi: 10.1080/13543784.2018.1420780. Epub 2017 Dec 28. Review.

PMID:
29271672
17.

Direct acting antiviral agents and hepatocellular carcinoma development: don't take it for granted.

Buonomo AR, Gentile I, Borgia G.

Transl Gastroenterol Hepatol. 2017 Dec 6;2:101. doi: 10.21037/tgh.2017.11.09. eCollection 2017. No abstract available.

18.

Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy.

Buonomo AR, Scotto R, Pinchera B, Coppola N, Monari C, Macera M, Borgia G, Gentile I.

New Microbiol. 2018 Jan;41(1):26-29. Epub 2017 Nov 7.

19.

Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis.

Fiore M, Maraolo AE, Gentile I, Borgia G, Leone S, Sansone P, Passavanti MB, Aurilio C, Pace MC.

World J Hepatol. 2017 Oct 28;9(30):1166-1175. doi: 10.4254/wjh.v9.i30.1166. Review.

20.

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.

Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG.

PLoS One. 2017 Oct 4;12(10):e0185728. doi: 10.1371/journal.pone.0185728. eCollection 2017.

21.

Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage.

Gentile I, Buonomo AR, Scotto R, Zappulo E, Borgia G.

Eur J Intern Med. 2017 Dec;46:e45-e47. doi: 10.1016/j.ejim.2017.09.014. Epub 2017 Sep 14. No abstract available.

PMID:
28918985
22.

Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis.

Buonomo AR, Zappulo E, Scotto R, Pinchera B, Perruolo G, Formisano P, Borgia G, Gentile I.

Int J Infect Dis. 2017 Oct;63:23-29. doi: 10.1016/j.ijid.2017.07.026. Epub 2017 Aug 10.

23.

Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.

Maraolo AE, Cascella M, Corcione S, Cuomo A, Nappa S, Borgia G, De Rosa FG, Gentile I.

Expert Rev Anti Infect Ther. 2017 Sep;15(9):861-871. doi: 10.1080/14787210.2017.1367666. Epub 2017 Aug 18. Review.

PMID:
28803496
24.

Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.

Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, Zignego AL, Ciancio A, Di Leo A, Raimondo G, Ferrari C, Taliani G, Borgia G, Santantonio TA, Blanc P, Gaeta GB, Gasbarrini A, Chessa L, Erne EM, Villa E, Ieluzzi D, Russo FP, Andreone P, Vinci M, Coppola C, Chemello L, Madonia S, Verucchi G, Persico M, Zuin M, Puoti M, Alberti A, Nardone G, Massari M, Montalto G, Foti G, Rumi MG, Quaranta MG, Cicchetti A, Craxì A, Vella S; PITER Collaborating Group.

Hepatology. 2017 Dec;66(6):1814-1825. doi: 10.1002/hep.29399. Epub 2017 Oct 30.

25.

Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review.

Fiore M, Maraolo AE, Gentile I, Borgia G, Leone S, Sansone P, Passavanti MB, Aurilio C, Pace MC.

World J Gastroenterol. 2017 Jul 7;23(25):4654-4660. doi: 10.3748/wjg.v23.i25.4654. Review.

26.

Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review.

Fiore M, Maraolo AE, Chiodini P, Cerchione C, Gentile I, Borgia G, Pace MC.

Cardiovasc Hematol Disord Drug Targets. 2017;17(2):105-110. doi: 10.2174/1871529X17666170703115545. Review.

PMID:
28676032
27.

Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection.

Gentile I, Buonomo AR, Scotto R, Zappulo E, Carriero C, Piccirillo M, Izzo F, Rizzo M, Cerasuolo D, Borgia G, Cavalcanti E.

In Vivo. 2017 Jul-Aug;31(4):695-700.

28.

Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.

Gentile I, Buonomo AR, Maraolo AE, Scotto R, De Zottis F, Di Renzo G, Borgia G.

J Antimicrob Chemother. 2017 Sep 1;72(9):2678-2679. doi: 10.1093/jac/dkx172. No abstract available.

PMID:
28575437
29.

Prevalence of Congenital Cytomegalovirus Infection Assessed Through Viral Genome Detection in Dried Blood Spots in Children with Autism Spectrum Disorders.

Gentile I, Zappulo E, Riccio MP, Binda S, Bubba L, Pellegrinelli L, Scognamiglio D, Operto F, Margari L, Borgia G, Bravaccio C.

In Vivo. 2017 May-Jun;31(3):467-473.

30.

Hepatitis B mother-to-child transmission and infants immunization: we have not come to the end of the story yet.

Borgia G, Maraolo AE, Gentile I.

Infect Dis (Lond). 2017 Aug;49(8):584-587. doi: 10.1080/23744235.2017.1303746. Epub 2017 Mar 20. No abstract available.

PMID:
28316268
31.

ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.

Coppola N, De Pascalis S, Messina V, Di Caprio G, Martini S, de Stefano G, Starace M, Stornaiuolo G, Stanzione M, Ascione T, Minichini C, Sangiovanni V, Zampino R, Calò F, Rinaldi L, Persico M, Federico A, Buonomo AR, Borgia G, Gaeta GB, Filippini P, Gentile I.

Antivir Ther. 2017;22(7):551-558. doi: 10.3851/IMP3134. Epub 2017 Feb 6.

PMID:
28165327
32.

Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.

Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M.

Expert Rev Gastroenterol Hepatol. 2016 Nov;10(11):1227-1234. Epub 2016 Sep 16. Review.

PMID:
27607920
33.

What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?

Gentile I, Maraolo AE, Borgia G.

Expert Rev Anti Infect Ther. 2016 Oct;14(10):875-8. doi: 10.1080/14787210.2016.1233060. No abstract available.

PMID:
27599088
34.

The therapeutic potential of new investigational hepatitis C virus translation inhibitors.

Borgia G, Maraolo AE, Buonomo AR, Scotto R, Gentile I.

Expert Opin Investig Drugs. 2016 Oct;25(10):1209-14. doi: 10.1080/13543784.2016.1225036. Epub 2016 Aug 28. Review.

PMID:
27537604
35.

Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.

Gentile I, Scotto R, Zappulo E, Buonomo AR, Pinchera B, Borgia G.

Expert Opin Investig Drugs. 2016;25(5):557-72. doi: 10.1517/13543784.2016.1161023. Epub 2016 Mar 21. Review.

PMID:
26934419
36.

The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C.

Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G.

Expert Opin Drug Discov. 2015 Dec;10(12):1363-77. doi: 10.1517/17460441.2015.1094051. Epub 2015 Nov 12.

PMID:
26563720
37.

Asunaprevir for hepatitis C: a safety evaluation.

Gentile I, Zappulo E, Buonomo AR, Scotto R, Borgia G.

Expert Opin Drug Saf. 2015 Oct;14(10):1631-46. doi: 10.1517/14740338.2015.1084287. Epub 2015 Sep 2. Review.

PMID:
26329454
38.

Sustained low influenza vaccination in health care workers after H1N1 pandemic: a cross sectional study in an Italian health care setting for at-risk patients.

Giannattasio A, Mariano M, Romano R, Chiatto F, Liguoro I, Borgia G, Guarino A, Lo Vecchio A.

BMC Infect Dis. 2015 Aug 12;15:329. doi: 10.1186/s12879-015-1090-x.

39.

Beclabuvir for the treatment of hepatitis C.

Gentile I, Zappulo E, Buonomo AR, Maraolo AE, Borgia G.

Expert Opin Investig Drugs. 2015;24(8):1111-21. doi: 10.1517/13543784.2015.1059820. Epub 2015 Jul 9. Review.

PMID:
26156630
40.

Fecal microbiota transplantation for Clostridium difficile infection: back to the future.

Borgia G, Maraolo AE, Foggia M, Buonomo AR, Gentile I.

Expert Opin Biol Ther. 2015 Jul;15(7):1001-14. doi: 10.1517/14712598.2015.1045872. Review.

PMID:
26063385
41.

Low vitamin D levels are associated with the presence of serum cryoglobulins in patients with chronic HCV infection.

Gentile I, Scarano F, Celotti A, DE Iuliis E, Scarano R, Granata V, Pinchera B, Meola M, D'Ambra A, Piccirillo M, DI Paola F, Cavalcanti E, Izzo F, Scarpato N, Borgia G.

In Vivo. 2015 May-Jun;29(3):399-404.

PMID:
25977388
42.

A pill a day keeps HCV away.

Gentile I, Borgia G.

Lancet Infect Dis. 2015 Jun;15(6):616-7. doi: 10.1016/S1473-3099(15)70127-1. Epub 2015 Apr 8. No abstract available.

PMID:
25863561
43.

A survey on antibiotic therapy knowledge among physicians of a tertiary care and university hospital.

Gentile I, Landolfo D, Buonomo AR, Crispo M, Iula VD, Minei G, Catania MR, Borgia G.

Infez Med. 2015 Mar;23(1):12-7.

44.

Discontinued drugs in 2012 - 2013: hepatitis C virus infection.

Gentile I, Buonomo AR, Zappulo E, Borgia G.

Expert Opin Investig Drugs. 2015 Feb;24(2):239-51. doi: 10.1517/13543784.2015.982274. Epub 2014 Nov 11.

PMID:
25384989
45.

GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.

Gentile I, Buonomo AR, Zappulo E, Coppola N, Borgia G.

Expert Rev Anti Infect Ther. 2014 Oct;12(10):1179-86. doi: 10.1586/14787210.2014.945432. Epub 2014 Aug 5. Review.

PMID:
25096404
46.

Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.

Gentile I, Buonomo AR, Borgia G.

Expert Rev Anti Infect Ther. 2014 Sep;12(9):1033-43. doi: 10.1586/14787210.2014.940898. Epub 2014 Jul 30. Review.

PMID:
25074011
47.

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.

Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G.

Ther Clin Risk Manag. 2014 Jun 26;10:493-504. doi: 10.2147/TCRM.S66731. eCollection 2014. Review.

48.
49.

ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.

Gentile I, Borgia F, Buonomo AR, Zappulo E, Castaldo G, Borgia G.

Curr Med Chem. 2014;21(28):3261-70. Review.

PMID:
25005190
50.

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency.

Rosina F, Tosti ME, Borghesio E, Masocco M, Mele A, Coppola C, Milella M, Borgia G, Andreone P, Koch M, Zignego AL, Romano M, Carrara M, Almasio PL, Azzola E, Nardone G, Benedetti A, Carosi G, Mazzotta F, Sagnelli E, Rizzetto M; AIFA Study Group; Italian Association for the Study of the Liver (AISF); Italian Society for Infectious and Tropical Diseases (SIMIT); Italian Association of Hospital Gastroenterologists (AIGO); Italian Society of Gastroenterology (SIGE); Italian Association for the Study of the Liver AISF; Italian Society for Infectious and Tropical Diseases SIMIT; Italian Association of Hospital Gastroenterologists AIGO; Italian Society of Gastroenterology SIGE.

Dig Liver Dis. 2014 Sep;46(9):826-32. doi: 10.1016/j.dld.2014.05.014. Epub 2014 Jun 28.

PMID:
24986781

Supplemental Content

Loading ...
Support Center